Clinical trial NCT06560060: Do People With Complications of Type 1 Diabetes Mellitus Have a Different Microbiome (MARVEL)
Official title: Is the Gut Microbiome Associated With Residual Β-Cell Function and DeVElopment of Complications in Individuals With Longstanding Type 1 Diabetes Mellitus (MARVEL)
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Type 1 Diabetes
Keywords: Microbiome
Type 1 diabetes
Complications
Betacell function
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
Collaborators: name: Diabeter Nederland BV
First posted: 2024-08-19
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The source population are patients with T1D in the Amsterdam region visiting the Diabeter Center Amsterdam which takes care for around +/- 5000 individuals with T1D.

Brief summary: This study looks at whether people with type 1 diabetes have different gut bacteria. We also want to see if this is linked to keeping insulin production up and preventing complications like heart disease and nerve damage. The aim is to find ways to keep more of the functions working, avoid low blood sugar and reduce diabetes complications.

Detailed description: Rationale: It has become apparent that most individuals with type 1 diabetes mellitus (T1D) have some remaining β-cell function. Individuals with T1D and a preserved β-cell function have a lower risk of hypoglycemia and diabetic complications. The factors regulating residual β-cell function are unknown. A likely mechanism leading to β-cell preservation is regulation of immunological tone by the gut microbiome. Recently we published in a small pilot cohort (GUTDM1, METC 2020_105) that residual β-cell function is linked to better glycemic control (time in range) and linked to specific gut microbiota composition. Since this cohort was too small to also show a link with presence of diabetic complications and recruit enough individuals with preserved β-cell function for confirmatory intervention trials to increase β-cell function, we will now aim to recruit a larger follow-up cohort. The aim of this cohort is to a) investigate whether residual β-cell function is associated with gut microbiome composition and circulating immune cell counts in individuals with T1D and diabetic complications b) identify 500 potential eligible individuals with preserved β-cell function for future intervention trials.

Objective:

1. To investigate whether T1D individuals with preserved β-cell function exhibit a distinct gut microbial and circulating immune cell signature, leading to a reduced incidence of diabetes complications (CVD, nephropathy, neuropathy, and retinopathy).
2. Identify individuals with preserved β-cell function for diagnostics as well as future intervention studies to increase β-cell function.

Study design: 10-year longitudinal observational multicenter cohort study

Study population: 5000 individuals with type 1 diabetes \>18 years of age, visiting the outpatient clinic of Diabeter center Amsterdam and Diabeter Nederland.

Main study parameters/endpoints: The primary endpoint is long-term residual β-cell function as assessed by baseline and stimulated 2-hour post meal urinary C-peptide levels at 3,6 and 10 years follow-up. The secondary endpoint pertains presence and incidence of diabetes complications (cardiovascular disease, nephropathy, neuropathy and retinopathy), gut microbiota composition measured in feces with shotgun sequencing, glucose time-in-range (CGM-metrics) and subsequent exogenous insulin dose. Tertiary endpoints include the profiling of immune cell subsets, assessment of autoreactive T lymphocytes and HLA typing by high resolution sequencing of circulating leukocytes (IMMOCHIP) in relation to untargeted plasma metabolomics (Metabolon).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: This study is considered a negligible-risk study. The patient will complete several questionnaires, keep track of a food diary and collect urine and feces prior to the baseline study visit. At the study visit we will require a fasted plasma sample, this will slightly increase the chances of a hypoglycemic episode, largely mitigated because all participants carry a continues glucose monitor. Additionally, we will calculate BMI, waist circumference, liver stiffness and measure blood pressure. The questionnaires inquire about the burden of diabetic complications, socio-economic status and financial literacy, abdominal complaints and hypoglycemic episodes, and comorbidities associated with diabetes, quality of life and psychological functioning. We argue that the risk and discomfort associated with this study is similar to the yearly diabetes check-up and justified in light of the potentially profound insights and novel treatments to be gained by studying the impact of the gut microbiome on residual β-cell function in T1D.

Eligibility criteria: Inclusion Criteria:

* All individuals with T1D visiting the outpatient clinic of Diabeter Center Amsterdam or Diabeter Nederland are potentially eligible if they are \>18 years old.
* T1D diagnosis is made by the primary clinician prior to the study visit. Presence of auto- antibodies at time of diagnosis will be recorded.

Exclusion Criteria:

* Active infection during the study visit
* Inability or unwillingness to donate feces or urine.
* Smoking or illicit drug use (e.g. MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or use during the study period.
* Inability or unwillingness to provide informed consent.
* Absence of a large bowel (ie colostomy)

Primary outcomes:
measure: Residual β-cell insulin secretion capacity:
timeFrame: At 0,3,6 and 10 years follow-up.
Secondary outcomes:
measure: Presence and incidence of diabetes complications
timeFrame: At 0, 3, 6 and 10 years follow up
measure: Glycemic control:
timeFrame: At 0,3,6 and 10 years follow-up.
measure: Intestinal microbiota composition
timeFrame: At 0,3,6 and 10 years follow-up.
Other outcomes:
measure: Circulating microbiota-derived metabolites
timeFrame: At 0,3,6 and 10 years follow-up.
measure: Autoimmunity markers
timeFrame: At 0,3,6 and 10 years follow-up.
Locations:
Study officials:
affiliation: Diabeter Center Amsterdam/Diabeter Nederland
name: Henk-Jan Aanstoot, Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Dept of Vascular Medicine, Amsterdam UMC - AMC
name: Max Nieuwdorp, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Dept of Vascular Medicine, Amsterdam UMC - AMC
name: Nordin Hanssen, Dr.
role: PRINCIPAL_INVESTIGATOR
References: